Mining incretin hormone pathways for novel therapies

Trends in Endocrinology and Metabolism

Volumn 20, Issue 6, 2009, Pages 280-286

  Wideman, Rhonda D ^a   Kieffer, Timothy J ^a,b  

^a Life Sciences Institute   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; PROGLUCAGON; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

BARIATRIC SURGERY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; ENTEROENDOCRINE CELL; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREATITIS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REMISSION; REVIEW; STOMACH BYPASS; STOMACH EMPTYING; WEIGHT REDUCTION;

ANIMALS; BARIATRIC SURGERY; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG DISCOVERY; EATING; ENTEROENDOCRINE CELLS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; ISLETS OF LANGERHANS; MOLECULAR MIMICRY; OBESITY;

EID: 68149161100     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.02.005     Document Type: Review

References (96)

1. McIntyre N., et al. New interpretation of oral glucose tolerance. Lancet 41 (1964) 20-21
2. Labarre J. Sur les possibilities d'un traitement due diabete par l'incretine. Bull. Acad. R. Med. Belg. 12 (1932) 620-634
3. Creutzfeldt W., and Ebert R. New developments in the incretin concept. Diabetologia 28 (1985) 565-573
4. Brown J.C., and Dryburgh J.R. A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can. J. Biochem. 49 (1971) 867-872
5. Pederson R.A., and Brown J.C. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99 (1976) 780-785
6. Ross S.A., and Dupre J. Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects. Diabetes 27 (1978) 327-333
7. Kieffer T.J., and Habener J.F. The glucagon-like peptides. Endocr. Rev. 20 (1999) 876-913
8. Wideman R.D., and Kieffer T.J. Glucose-dependent insulinotropic polypeptide as a regulator of beta cell function and fate. Horm. Metab. Res. 36 (2004) 782-786
9. Nikolaidis L.A., et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H2401-H2408
10. Ban K., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117 (2008) 2340-2350
11. Sokos G.G., et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am. J. Cardiol. 100 (2007) 824-829
12. Sonne D.P., et al. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul. Pept. 146 (2008) 243-249
13. Ding K.H., et al. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J. Bone Miner. Res. 23 (2008) 536-543
14. Xie D., et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 40 (2007) 1352-1360
15. Meier J.J., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46 (2003) 798-801
16. Theodorakis M.J., et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am. J. Physiol. Endocrinol. Metab. 290 (2006) E550-E559
17. Mortensen K., et al. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 114 (2003) 189-196
18. Fujita Y., et al. Pax6 and Pdx1 are required for production of glucose-dependent insulinotropic polypeptide in proglucagon-expressing L cells. Am. J. Physiol. Endocrinol. Metab. 295 (2008) E648-E657
19. Ugleholdt R., et al. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 145 (2004) 1349-1355
20. Zhu X., et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10293-10298
21. Ugleholdt R., et al. Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. J. Biol. Chem. 281 (2006) 11050-11057
22. Masur K., et al. Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining beta-cell function. Mol. Endocrinol. 19 (2005) 1373-1382
23. Wilson M.E., et al. Expression pattern of IAPP and prohormone convertase 1/3 reveals a distinctive set of endocrine cells in the embryonic pancreas. Mech. Dev. 115 (2002) 171-176
24. Thyssen S., et al. Ontogeny of regeneration of beta-cells in the neonatal rat after treatment with streptozotocin. Endocrinology 147 (2006) 2346-2356
25. Nie Y., et al. Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J. Clin. Invest. 105 (2000) 955-965
26. Wideman R.D., et al. Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1). Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13468-13473
27. Wideman R.D., et al. A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice. Diabetes 56 (2007) 2744-2752
28. Wideman R.D., et al. Transplantation of PC1/3-expressing alpha-cells improves glucose handling and cold tolerance in leptin-resistant mice. Mol. Ther. 17 (2009) 191-198
29. Ahren B., et al. GIP-like immunoreactivity in glucagon cells. Interactions between GIP and glucagon on insulin release. Acta Physiol. Scand. 112 (1981) 233-242
30. Alumets J., et al. Is GIP a glucagon cell constituent?. Histochemistry 58 (1978) 253-257
31. Smith P.H., et al. Immunocytochemical localization of a gastric imhibitory polypeptide-like material within A-cells of the endocrine pancreas. Am. J. Anat. 149 (1977) 585-590
32. Sjolund K., et al. Gastric inhibitory peptide-like immunoreactivity in glucagon and glicentin cells: properties and origin. An immunocytochemical study using several antisera. J. Histochem. Cytochem. 31 (1983) 811-817
33. Smith P.H. Immunocytochemical localization of glucagonlike and gastric inhibitory polypeptidelike peptides in the pancreatic islets and gastrointestinal tract. Am. J. Anat. 168 (1983) 109-118
34. Secor S.M., et al. Responses of python gastrointestinal regulatory peptides to feeding. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13637-13642
35. Maletti M., et al. Evidence of functional gastric inhibitory polypeptide (GIP) receptors in human insulinoma. Binding of synthetic human GIP 1-31 and activation of adenylate cyclase. Diabetes 36 (1987) 1336-1340
36. Unger R.H., and Eisentraut A.M. Entero-insular axis. Arch. Intern. Med. 123 (1969) 261-266
37. Lim G.E., and Brubaker P.L. Glucagon-like peptide 1 secretion by the L-cell: the view from within. Diabetes 55 (2006) S70-S77
38. Kieffer T.J., et al. Release of gastric inhibitory polypeptide from cultured canine endocrine cells. Am. J. Physiol. 267 (1994) E489-E496
39. Roberge J.N., and Brubaker P.L. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133 (1993) 233-240
40. Jang H.J., et al. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 15069-15074
41. Fujita Y., et al. Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. Am. J. Physiol. Endocrinol. Metab (2008)
42. Parker H.E., et al. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52 (2009) 289-298
43. Reimann F., et al. Glucose sensing in L cells: a primary cell study. Cell Metab. 8 (2008) 532-539
44. Nauck M., et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-52
45. Vilsboll T., et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50 (2001) 609-613
46. Nauck M.A., et al. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53 suppl. 3 (2004) S190-S196
47. Eng J., et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267 (1992) 7402-7405
48. Kolterman O.G., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 62 (2005) 173-181
49. Ahmad S.R., and Swann J. Exenatide and rare adverse events. N. Engl. J. Med. 358 (2008) 1970-1971
50. Fehse F., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 90 (2005) 5991-5997
51. Kendall D.M., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
52. Garber A., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 (2009) 473-478
53. Juhl C.B., et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51 (2002) 424-429
54. Baggio L.L., et al. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 134 (2008) 1137-1147
55. Herman G.A., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91 (2006) 4612-4619
56. He Y.L., et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin. Pharmacokinet. 46 (2007) 577-588
57. Vella A., et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56 (2007) 1475-1480
58. Bosi E., et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30 (2007) 890-895
59. Hansotia T., et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53 (2004) 1326-1335
60. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30 (2007) 1335-1343
61. Qian F., et al. Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. Int. J. Pharm. 366 (2009) 218-220
62. Knudsen L.B., et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 937-942
63. Su H., et al. Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS One 3 (2008) e2892
64. Chen D., et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 943-948
65. Joseph J.W., et al. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia 43 (2000) 1319-1328
66. Beglinger C., et al. Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin Pharmacol Ther (2008)
67. Gutniak M.K., et al. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 19 (1996) 843-848
68. Gutniak M.K., et al. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 20 (1997) 1874-1879
69. Itoh Y., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422 (2003) 173-176
70. Edfalk S., et al. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57 (2008) 2280-2287
71. Hirasawa A., et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 11 (2005) 90-94
72. Katsuma S., et al. Free fatty acids inhibit serum deprivation-induced apoptosis through GPR120 in a murine enteroendocrine cell line STC-1. J. Biol. Chem. 280 (2005) 19507-19515
73. Chu Z.L., et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148 (2007) 2601-2609
74. Chu Z.L., et al. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149 (2008) 2038-2047
75. Lauffer L., et al. GPR119: "double-dipping" for better glycemic control. Endocrinology 149 (2008) 2035-2037
76. Soltani N., et al. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther. 14 (2007) 981-988
77. Parsons G.B., et al. Ectopic expression of glucagon-like peptide 1 for gene therapy of type II diabetes. Gene Ther. 14 (2007) 38-48
78. Tseng C.C., et al. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J. Clin. Invest. 98 (1996) 2440-2445
79. Nauck M.A., et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91 (1993) 301-307
80. Althage M.C., et al. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J. Biol. Chem. 283 (2008) 18365-18376
81. Miyawaki K., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 14843-14847
82. McClean P.L., et al. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am. J. Physiol. Endocrinol. Metab. 293 (2007) E1746-E1755
83. Irwin N., et al. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. Biol Chem (2008)
84. Fulurija A., et al. Vaccination against GIP for the treatment of obesity. PLoS One 3 (2008) e3163
85. Bose M., et al. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence?. Obes. Surg. 19 (2009) 217-229
86. Laferrere B., et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 93 (2008) 2479-2485
87. Laferrere B., et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30 (2007) 1709-1716
88. Naslund E., et al. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes. Surg. 8 (1998) 253-260
89. Goldfine A.B., et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J. Clin. Endocrinol. Metab. 92 (2007) 4678-4685
90. Patriti A., et al. How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced proglucagon gene expression and L-cell number. Surgery 142 (2007) 74-85
91. Patriti A., et al. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes. Surg. 15 (2005) 1258-1264
92. Vella A., and Service F.J. Incretin hypersecretion in post-gastric bypass hypoglycemia - primary problem or red herring?. J. Clin. Endocrinol. Metab. 92 (2007) 4563-4565
93. Cummings D.E. Gastric bypass and nesidioblastosis - too much of a good thing for islets?. N. Engl. J. Med. 353 (2005) 300-302
94. Troy S., et al. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab. 8 (2008) 201-211
95. Fritsch H.A.R., et al. Cytochemical and immunofluorescence investigations on insulin-like producing cells in the intestine of Mytilus edulis L. (Bivalvia). Cell Tissue Res. 165 (1976) 365-369
96. Emdin S.O., and Falkmer S. Phylogeny of insulin. Some evolutionary aspects of insulin production with particular regard to the biosynthesis of insulin in Myxine glutinosa. Acta Paediatr. Scand. Suppl. 270 (1977) 15-25